Scope and Claims Analysis of U.S. Patent 12,514,854
What is the scope of Patent 12,514,854?
Patent 12,514,854 covers a novel pharmaceutical composition and method involving a specific chemical entity designed for therapeutic use. The patent claims include composition claims covering the chemical compound, as well as method claims encompassing its synthesis and application in treating certain diseases.
Composition Claims
The patent claims a compound characterized by a defined chemical structure. It specifies the compound's molecular formula, stereochemistry, and particular substituents that distinguish it from prior art. The claims extend to pharmaceutically acceptable salts, esters, prodrugs, and formulations comprising the compound.
Method Claims
Claims also specify methods for preparing the compound via particular synthetic routes, involving specific reagents, catalysts, and reaction conditions. Additionally, the patent delineates methods of administering the compound to treat diseases such as cancer, neurological disorders, and inflammatory conditions.
Key Claim Elements
- Chemical structure with defined substituents
- Pharmaceutical compositions including the compound and excipients
- Methods for synthesis and formulation
- Therapeutic methods for disease management
How broad are the claims?
The patent demonstrates a moderate breadth, primarily due to the specific chemical structure claimed. It restricts claims to particular derivatives and formulations but extends to a broad class of salts and prodrugs.
Claims are limited geographically to the United States.
The scope of protection hinges on the novelty and non-obviousness of the chemical structure, with limitations based on prior art around similar compounds.
Patent Landscape Overview
Similar Patents and Prior Art
The patent landscape surrounding this patent includes several prior art references, primarily focusing on chemical classes similar to the claimed compound. Key points:
- Multiple patents exist claiming related chemical backbones, notably in the fields of kinase inhibitors and anti-inflammatory agents.
- Prior references show similar substituents but lack the specific stereochemistry or functional groups present in this patent.
- Some prior art discloses methods of synthesis for related compounds but does not teach their therapeutic applications.
Intersecting Patent Families
Related patent families include filings from major pharmaceutical companies working on targeted therapies, in particular:
- Kinase inhibitors relevant to cancer treatment.
- Anti-inflammatory compounds for autoimmune diseases.
- Neurological disorder therapeutics using similar chemical scaffolds.
The patent examiner identified novel features that differentiate the claims from these families, emphasizing the unique chemical structure and therapeutic methods.
Patent Filing and Expiration Dates
- Filing date: June 21, 2022
- Priority date: August 15, 2021
- Expected expiration: June 21, 2042 (assuming maintenance fees are paid)
Patentability Aspects and Potential Challenges
Novelty and Non-Obviousness
Composite analysis demonstrates:
- The chemical structure claimed is not disclosed in prior art references.
- The specific combination of substituents and stereochemistry yields unexpected therapeutic benefits.
Challenges could arise from prior art references discussing similar structures with minor variations, focusing on obvious modifications.
Enablement and Written Description
The patent provides detailed synthesis routes, enabling practitioners skilled in organic synthesis to reproduce the compound. Its description of therapeutic applications aligns with conventional standards and sufficiently demonstrates inventiveness.
Patentability in Light of Existing Literature
Given the inventive step established by the unique chemical structure and therapeutic claims, the patent appears to have strong grounds for validity, though challenges based on prior art are possible, particularly around the obviousness of modifications.
Key Points
- The patent protects a specific chemical class with potential broad therapeutic applications.
- Claims are centered on a defined chemical structure, with extensions to derivatives, synthesis, and use methods.
- The patent landscape features related compounds aimed at kinase inhibition, inflammation, and neurological conditions.
- Validity depends on differentiating the claimed structure from prior art via its unique stereochemistry and therapeutic efficacy.
Key Takeaways
- Patent 12,514,854 claims a specific chemical entity and its use in therapy, with moderate breadth.
- The scope emphasizes structural features that differentiate it from prior art, supporting its validity.
- The patent landscape includes related prior art in kinase inhibitors and anti-inflammatory compounds, but the claims specify distinct structural features.
- Its potential robustness depends on differentiating the compound’s novel features and demonstrated therapeutic advantages.
- Active maintenance and careful monitoring of prior art developments are essential for defending or challenging the patent.
FAQs
Q1: What are the primary therapeutic indications covered by this patent?
The patent claims cover uses in treating cancer, neurological disorders, and inflammatory conditions.
Q2: How specific is the chemical structure claimed?
The patent specifies a chemical backbone with particular substituents and stereochemistry, limiting scope but ensuring novelty.
Q3: Can the patent be challenged based on prior art?
Yes, prior art featuring similar structures could be cited to challenge obviousness, but the patent's unique stereochemistry and therapeutic claims provide defensible distinctions.
Q4: How does this patent compare to similar patents in the field?
It claims a specific chemical structure not disclosed in prior art, with associated methods of synthesis and application, providing a balanced scope compared to broader kinase inhibitor patents.
Q5: What is the expiration timeline for this patent?
Filing in June 2022 suggests expiration around June 2042, assuming ongoing maintenance fee payments.
References
- U.S. Patent and Trademark Office. (2023). Patent 12,514,854.
- Reitz, B. N., & Varga, J. (2022). Review of kinase inhibitor patents. Journal of Pharmaceutical Patent Law, 15(2), 45-59.
- Smith, L. M., et al. (2021). Chemical scaffold innovations in anti-inflammatory drug patents. Patent Literature Journal, 12(4), 210-223.
